


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/574, 33/573, C12Q 1/37		A1	(11) International Publication Number: WO 99/32887
			(43) International Publication Date: 1 July 1999 (01.07.99)
(21) International Application Number: PCT/US98/25571 (22) International Filing Date: 3 December 1998 (03.12.98) (30) Priority Data: 08/985,121 4 December 1997 (04.12.97) US (71) Applicant: GUILFORD PHARMACEUTICALS INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US). (72) Inventors: SLUSHER, Barbara, S. ; 7424 Longfield Drive, Kingsville, MD 21087 (US). LAPIDUS, Rena, S. ; 713 Sudbrook Road, Baltimore, MD 21208 (US). (74) Agent: NATH, Gary, M. ; Nath & Associates, 6th floor, 1030 15th Street, N.W., Washington, DC 20005 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: DETECTION OF PROSTATE DISEASE BY MEASURING NAALADASE ACTIVITY



(57) Abstract

The present invention relates to novel methods and kits for quantitating N-Acetylated α -Linked Acidic Dipeptidase (NAALADase) enzyme activity in biological samples, including prostate biopsies, seminal fluid, ejaculate, prostatic fluid, blood, saliva, and urine, for the purpose of identifying and differentiating between prostate carcinoma, benign prostatic hyperplasia, and normal prostate.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DETECTION OF PROSTATE DISEASE BY MEASURING NAALADASE ACTIVITY

5

BACKGROUND OF THE INVENTION1. Field of the Invention

The present invention relates generally to the field of prostate cancer, and particularly, to methods and kits for assaying NAALADase activity in a sample to differentiate between prostate cancer, benign prostatic hyperplasia (BPH), and normal prostate tissue.

2. Description of the Prior Art

15

Prostate Cancer

Prostate cancer is the leading form of cancer and the second leading cause of death from cancer for men in the United States. The American Cancer Society has estimated that in 1996 alone, 317,100 new cases of prostate cancer were diagnosed and 41,400 deaths were caused by prostate cancer. The incidence rate of prostate cancer increased 65% between 1980 and 1990, and will continue to rise with improved screening tests and longer life expectancies. While most men used to die of other illnesses before prostate cancer had a chance to develop, higher prostate cancer mortality rates are expected as men live longer and the disease has more time to progress.

-2-

There is a recognized need for earlier, more effective means of detection of malignant prostate cancer, since only 3-4% of all prostate carcinomas are currently detected by routine screening (Brawer
5 et al., 1992).

Currently available diagnostic techniques include pathohistology of prostate biopsies, digital rectal examination (DRE), transrectal
ultrasonography (TRUS), and assaying prostate-
10 specific antigen.

Pathohistology of prostate tissue can definitively identify prostate cancer in many cases. However, there are limitations to this method of screening. First, the Gleason's grading scale used
15 by pathologists is at best semi-quantitative since it may be difficult to search every cell of every tissue slice. Second, one pathologist's thresholds of scoring often do not coincide with the scores given by other pathologists. For these reasons
20 Gleason scores themselves have limited quantitative value.

DRE and TRUS are widely employed by diagnosticians but are very limited in their ability to diagnose prostate cancer and do not provide the
25 ability to distinguish benign prostatic hyperplasia and prostate cancer.

Assaying for PSA in a patient's serum has been shown to be a good predictor of prostate cancer.

However, a commonly cited difficulty with this tool is that both prostate cancer and BPH give rise to elevated PSA values. A study of the rate of PSA elevation over many months and years shows that PSA
5 elevates at a slightly higher rate in prostate cancer versus BPH. However, the work is retrospective and the patients have to wait years before the outcome is apparent. Accordingly, the diagnostician cannot easily and quickly
10 differentiate between prostate cancer and BPH using PSA values.

NAALADase and the CNS

NAAG and NAALADase have been historically
15 implicated in several human and animal pathological conditions relating to the CNS. For example, it has been demonstrated that intra-hippocampal injections of NAAG elicit prolonged seizure activity. More recently, it was reported that rats genetically
20 prone to epileptic seizures have a persistent increase in their basal level of NAALADase activity. These observations support the hypothesis that increased availability of synaptic glutamate elevates seizure susceptibility, and suggest that
25 NAALADase inhibitors may provide anti-epileptic activity.

NAAG and NAALADase have also been implicated in the pathogenesis of ALS and in the pathologically

similar animal disease called Hereditary Canine Spinal Muscular Atrophy (HCSMA). It has been shown that concentrations of NAAG and its metabolites NAA, glutamate and aspartate -- are elevated two- to three-fold in the cerebrospinal fluid of ALS patients and HCSMA dogs. Additionally, NAALADase activity is significantly increased (two- to three-fold) in post-mortem spinal cord tissue from ALS patients and HCSMA dogs. As such, NAALADase inhibitors may be clinically useful in curbing the progression of ALS if increased metabolism of NAAG is responsible for the alterations of CSF levels of these acidic amino acids and peptides.

Abnormalities in NAAG levels and NAALADase activity have also been documented in post-mortem schizophrenic brain, specifically in the prefrontal and limbic brain regions.

NAALADase and the Prostate

In 1993, the molecular cloning of Prostate Specific Membrane Antigen (PSMA) was reported as a potential prostate carcinoma marker and hypothesized to serve as a target for imaging and cytotoxic treatment modalities for prostate cancer. This lead to the testing of NAALADase inhibitors on the growth of LNCAP cells (a cancer cell line). PSMA antibodies, particularly indium-111 labelled and itrium labelled PSMA antibodies, have been described

and examined clinically for the diagnosis and treatment of prostate cancer. PSMA is expressed in prostatic ductal epithelium and is present in seminal plasma, prostatic fluid and blood of prostate cancer patients. Surprisingly, it was found in 1996 that the expression of PSMA cDNA confers the activity of NAALADase.

However, prior to the present invention it has not been shown that the native PSMA enzyme in the prostate actually exhibits NAALADase activity, nor has NAALADase activity been found to be an indicator of the development of prostate tumors or to have any correlation to the pathological state of prostate tissue.

Despite many recent advances in the diagnosis of prostate cancer, it is evident that there exists no fast, reliable, or efficient method for differentiating between prostate cancer and BPH. The current lack of knowledge in the area of diagnosing abnormal prostate cell growth makes patient prognosis uncertain and complicates clinical treatment decisions.

SUMMARY OF THE INVENTION

Accordingly, the present invention is based upon the surprising discovery that NAALADase activity can be used to differentiate between normal prostate tissue, benign prostatic hyperplasia (BPH),

and prostate cancer.

In particular, the present invention is directed to a method for detecting or identifying benign prostatic hyperplasia (BPH) or prostate cancer, comprising: comparing NAALADase activity in
5 a sample of prostate tissue or bodily fluid to a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby
10 differential NAALADase activity between the NAALADase activity in the sample of prostate tissue or bodily fluid and the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate
15 cancer detects or identifies benign prostatic hyperplasia (BPH) or prostate cancer.

The present invention also relates to a method for detecting or identifying benign prostatic hyperplasia (BPH) or prostate cancer, comprising:
20 assaying NAALADase activity in a sample of prostate tissue or bodily fluid; and comparing the NAALADase activity in the sample of prostate tissue or bodily fluid to a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic
25 hyperplasia, or prostate cancer, whereby differential NAALADase activity between the NAALADase activity in the sample of prostate tissue or bodily fluid and the reference which correlates

to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies benign prostatic hyperplasia (BPH) or prostate cancer.

5 The present invention also provides a method for detecting or identifying a pathological condition of prostate tissue, comprising: assaying a sample of prostate tissue or a bodily fluid for NAALADase activity; and comparing the NAALADase activity of the sample of prostate tissue or bodily fluid to known NAALADase activity for normal prostate, benign prostatic hyperplasia, or prostate cancer, whereby differential NAALADase activity between the sample of prostate tissue or bodily fluid and the normal prostate, benign prostatic hyperplasia, or prostate cancer detects or identifies the pathological condition of the prostate tissue.

20 The present invention further includes a method for detecting or identifying benign prostatic hyperplasia or prostate cancer, comprising measuring or assaying NAALADase activity in a sample of prostate tissue or bodily fluid wherein the NAALADase activity on a detectable or labeled substrate of NAALADase results in a quantity of detectable or labeled metabolite; and comparing the quantity of labeled metabolite from the sample of prostate tissue or bodily fluid to at least one

reference or control wherein the reference or control represents a quantity of labeled metabolite from prostate tissue or bodily fluid which is indicative of non-neoplastic conditions, and whereby differential activity between the detectable or labeled metabolite from the sample of prostate tissue or bodily fluid and the control or reference quantity of labeled metabolite from normal prostate tissue or bodily fluid detects or identifies benign prostatic hyperplasia or prostate cancer.

The present invention is additionally directed to a method for detecting or identifying differential NAALADase activity in a sample of prostate tissue or bodily fluid, comprising: comparing NAALADase activity in a sample of prostate tissue or bodily fluid to a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby comparing NAALADase activity between the sample of prostate tissue or bodily fluid and the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies differential NAALADase activity.

The present invention further relates to a method for detecting or identifying differential NAALADase activity in both the membrane and cytosolic fractions of a sample of prostate tissue

or bodily fluid, comprising: comparing the ratio of
membrane NAALADase activity to cytosolic NAALADase
activity in a sample of prostate tissue or bodily
fluid to a reference which correlates to the ratio
5 of membrane NAALADase activity to cytosolic
NAALADase activity in normal prostate tissue, benign
prostatic hyperplasia, or prostate cancer, whereby
comparing NAALADase activity between the sample of
prostate tissue or bodily fluid and the reference
10 which correlates to the ratio of membrane NAALADase
activity to cytosolic NAALADase activity in normal
prostate tissue, benign prostatic hyperplasia (BPH),
or prostate cancer detects or identifies
differential NAALADase activity.

15 Preferably, the NAALADase activity in normal
prostate tissue, benign prostatic hyperplasia, or
prostate cancer is a quantitative value of a
detectable metabolite of NAALADase activity wherein
the detectable metabolite results from NAALADase
20 activity on a substrate selected from the group
consisting of N-Acetyl Aspartyl Glutamate (NAAG),
folate polyglutamate, derivatives thereof, and
substrates labeled with a radioactive marker,
chemiluminescent marker, enzymatic marker,
25 chromogenic marker, or other detectable marker.

Another preferred aspect of the present
invention includes a series of standards which
indicate a quantitative value of a detectable

metabolite of NAALADase activity, and in particular where the series of standards provides a gradient from lowest to highest NAALADase activity wherein benign prostatic hyperplasia exhibits a lower
5 quantitative value of the detectable metabolite than normal prostate tissue and wherein prostate cancer exhibits a higher quantitative value of the detectable metabolite than normal prostate tissue.

Another preferred aspect of the present
10 invention includes bodily fluids which are selected from the group consisting of seminal vesicle fluid, ejaculate, prostatic fluid, blood, saliva, and urine.

The present invention is also directed to kits
15 for performing the assays and methods disclosed herein. In one preferred embodiment, a kit is provided for detecting or identifying benign prostatic hyperplasia (BPH) or prostate cancer in a sample of prostate tissue or bodily fluid,
20 comprising: a detectable NAALADase enzyme substrate packaged in a container; and a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby differential NAALADase activity
25 between NAALADase activity in the sample of prostate tissue or bodily fluid and the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or

prostate cancer detects or identifies benign prostatic hyperplasia (BPH) or prostate cancer.

Another kit of the present invention is provided for detecting or identifying a pathological condition of a prostate in a sample of prostate tissue or bodily fluid, comprising: a detectable NAALADase enzyme substrate packaged in a container; and a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby differential NAALADase activity between NAALADase activity in the sample of prostate tissue or bodily fluid and the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies benign prostatic hyperplasia (BPH) or prostate cancer.

Yet another preferred kit of the present invention is provided for detecting or identifying differential NAALADase activity in a sample of prostate tissue or bodily fluid, comprising: a detectable NAALADase enzyme substrate packaged in a container; and a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer.

A further kit of the present invention is provided for detecting or identifying differential NAALADase activity in both the membrane and

cytosolic fractions of a sample of prostate tissue or bodily fluid, comprising: a detectable NAALADase enzyme substrate packaged in a container; and a reference which correlates to a ratio of membrane
5 NAALADase activity to cytosolic NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer.

In preferred kits, the substrate is selected from the group consisting of N-Acetyl Aspartyl
10 Glutamate (NAAG), folate polyglutamate, derivatives thereof, and substrates labeled with a radioactive marker, chemiluminescent marker, enzymatic marker, chromogenic marker, or other detectable marker.

Also in preferred kits of the present
15 invention, the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer is a series of standards showing a gradient from lowest to highest NAALADase activity wherein benign
20 prostatic hyperplasia exhibits a lower quantitative value of the detectable metabolite than normal prostate tissue and wherein prostate cancer exhibits a higher quantitative value of the detectable metabolite than normal prostate tissue.

25 The present inventive kits also provide for the testing of bodily fluids which are selected from the group consisting of seminal vesicle fluid, blood, saliva, ejaculate, prostatic fluid, and urine.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a bar graph showing that NAALADase enzyme activity (picomoles/minute/milligram) is remarkably significantly greater in prostate cancer (=45 pmol/min/mg) than in normal prostate tissue (5 pmol/min/mg).

FIG. 2 is a bar graph showing that NAALADase enzyme activity (picomoles/minute/milligram) is surprisingly significantly greater in prostate cancer (=45 pmol/min/mg) than in benign prostatic hyperplasia (=2 pmol/min/mg).

FIG. 3 is a bar graph showing that NAALADase enzyme activity (picomoles/minute/milligram) in benign prostatic hyperplasia (=2 pmol/min/mg) is significantly less than in normal prostate tissue (=5 pmol/min/mg).

FIG. 4 is a bar graph showing that the ratio of membrane versus cytosolic NAALADase enzyme activity is especially significantly greater in prostate cancer (ratio =5.9) than in benign prostatic hyperplasia (ratio =2.0) or normal prostate tissue (ratio =2.3).

DETAILED DESCRIPTION OF THE INVENTION


25

Definitions

"NAAG" refers to N-acetyl-aspartyl-glutamate, an important peptide component in the body. Studies suggest that NAAG may function as a neurotransmitter

and/or neuromodulator in the central nervous system,
or as a precursor of the neurotransmitter glutamate.

"NAALADase" refers to N-acetylated α -linked
acidic dipeptidase, a membrane-bound
5 metallopeptidase which catabolizes NAAG to N-
acetylaspartate (NAA) and glutamate:



Catabolism of NAAG by NAALADase

15

K_m of 540 nM. If NAAG is a bioactive peptide, then
NAALADase may serve to inactivate NAAG'S synaptic
action. Alternatively, if NAAG functions as a
precursor for glutamate, the primary function of
20 NAALADase may be to regulate synaptic glutamate
availability.

25 "Prostate disease" refers to any disease,
disorder or condition of the prostate, including
prostate cancer, such as adenocarcinoma or
metastatic cancers, and conditions characterized by
abnormal growth of prostatic epithelial cells, such

as benign prostatic hyperplasia.

"PSA" refers to Prostate Specific Antigen, a well known prostate cancer marker. It is a protein produced by prostate cells and is frequently present at elevated levels in the blood of men with prostate cancer. PSA correlates with tumor burden, serves as an indicator of metastatic involvement, and provides a parameter for following a prostate cancer patient's response to surgery, irradiation and androgen replacement therapy.

"PSMA" refers to Prostate Specific Membrane Antigen, a potential prostate carcinoma marker that has been hypothesized to serve as a target for imaging and cytotoxic treatment modalities for prostate cancer. PSMA is expressed in prostatic ductal epithelium and is present in seminal plasma, prostatic fluid and blood of cancer patients. It has been found that the expression of PSMA cDNA confers the activity of NAALADase.

LNCaP: an epithelial cell line derived from a human prostate tumor, which is androgen sensitive. The LNCaP cell line was derived from a supraclavicular lymph node metastasis of a human prostate carcinoma. Cells of this line exhibit increased proliferation in response to androgen, in vitro, and they secrete prostate specific antigen (PSA), a marker of differentiated epithelial cells.

IDENTIFYING: in the context of identifying

BPH, prostate adenocarcinoma, or other form of prostate cancer, ascertaining, establishing or otherwise determining one or more factual characteristics of benign prostatic hyperplasia, prostatic adenocarcinoma, or other form of prostate cancer.

METHODS OF USE OF THE PRESENT INVENTION

Protocol for Assaying NAALADase Enzyme Activity in Biological Samples

Fresh or frozen (-80°C) samples were resuspended in 10X volume of ice cold bakers water and minced by polytron. Following sonication, the sample preparation was centrifuged at 50,000Xg at 4°C for 20 min. The supernatant (cytosolic fraction) was removed, divided into 1 ml aliquots and frozen at -80°C. The pellet was then resuspended in half the original volume of 50mM Tris Cl buffer. This membrane fraction was again minced by polytron, sonicated and divided into 1 ml aliquots and frozen at -80°C. The NAALADase assay was performed as described by Slusher et al. (J. Biol. Chemistry 265:21297-21301, 1990). Briefly, CoCl₂ and tris-HCl pH 7.4 was added to known volumes of sample. Following the addition of N-acetyl-aspartate-L-³H-glutamate (NAAG), the sample was incubated at 37°C for 15 min and then passed through an ion exchange column to separate aspartate from

-17-

the labeled glutamate [flow through]. The samples are then counted on a Beckman LS 6000 beta scintillation counter. The assay is followed by a Biorad protein assay to determine specific activity for each sample.

The present invention relates to novel methods and kits for quantifying N-Acetylated α -Linked Acidic Dipeptidase (NAALADase) enzyme activity in biological samples, and more particularly, to differentiate between prostate carcinoma, benign prostatic hyperplasia and normal prostate. The present invention provides methods for quantitating NAALADase enzyme activity in biological samples, including prostate tissue, ejaculate, urine, blood, tears, lymph, sweat, saliva, sputum, seminal vesicle fluid, sperm, prostatic fluid, and assaying for the quantitative amount of NAALADase enzyme activity present in the sample.

The present invention contemplates using a variety of NAALADase enzyme substrates to measure the NAALADase enzyme activity in a biological sample. These substrates specifically include N-acetyl aspartyl glutamate, folate polyglutamate, and derivatives of the same labeled with radioactive, chemiluminescent, and enzymatic markers.

The detection systems that can be used in the process according to the present invention include

radioactivity scintillation counters, immunometric detection systems, colorimetric or densitometric based assays, spectrographic based assays, and analytical chromatographic assays.

5

The present invention further includes methods and kits for early identification of prostate cancer and benign prostatic hyperplasia by measuring the NAALADase enzyme activity of the fluids, excretions,
10 secretions and cells of the urogenitary tract and comparing this NAALADase enzyme activity to the differential NAALADase enzyme activity values known for normal prostate, benign prostatic hyperplasia, and prostate cancer thereby providing a reliable
15 differential diagnostic indicator of prostate pathology.

The present invention also relates to methods and kits for quantifying the NAALADase enzyme activity in membrane and cytosolic fractions of
20 prostate tissue, and using the ratio of membrane/cytosolic NAALADase enzyme activity to differentiate between benign prostatic hyperplasia and prostate cancer.

The present invention also contemplates using
25 the measured NAALADase activity to differentiate between prostate cancers which respond to hormone therapy treatments and prostate cancers which do not respond to hormone therapy treatments. In addition,

the present invention contemplates using the measured NAALADase activity to differentiate between non-metastatic prostate cancers and metastatic prostate cancers.

5 The present invention also contemplates using the measured NAALADase activity to screen for cancer recurrence or cancer metastasis in prostate cancer patients undergoing cancer treatment.

10 The present invention also contemplates a change in NAALADase enzyme activity through the modification of cellular machinery, inducer-suppressor proteins, nucleic acids, and compounds affecting the same.

15 FIG. 1 is a bar graph showing that NAALADase enzyme activity (picomoles/minute/milligram) is remarkably significantly greater in prostate cancer (≈ 45 pmol/min/mg) than in normal prostate tissue (5 pmol/min/mg). Prostates are removed from men undergoing radical prostatectomies as treatment for prostate cancer. After evaluation by a pathologist, 20 the prostates were separated histologically into normal, BPH and tumor sections. The frozen tissue samples were resuspended in 10X volume of ice cold bakers water and minced by polytron. Following 25 sonication, the tissue preparation was centrifuged at 50,000Xg at 4°C for 20 min. The supernatant (cytosolic fraction) was removed, divided into 1 ml aliquots and frozen at -80°C. The pellet was then

-20-

resuspended in half the original volume of 50mM Tris Cl buffer. This membrane fraction was again minced by polytron, sonicated and divided into 1 ml aliquots and frozen at -80°C. The NAALADase assay was performed as described by Slusher et al. (J. Biol. Chemistry 265:21297-21301, 1990). Briefly, CoCl₂ and tris-HCl pH 7.4 was added to known volumes of tissue extract. Following the addition of N-acetyl-aspartate-L-³H-glutamate (NAAG), the sample was incubated at 37°C for 15 min and then passed through an ion exchange column to separate aspartate from the labeled glutamate [flow through]. The samples are then counted on a Beckman LS 6000 beta scintillation counter. The assay is followed by a Biorad protein assay to determine specific activity for each sample as a measure of picomoles of labeled glutamate per minute of incubated exposure of labeled substrate to NAALADase enzyme per milligram of prepared sample exposed to substrate.

FIG. 2 is a bar graph showing that NAALADase enzyme activity (picomoles/minute/milligram) is surprisingly significantly greater in prostate cancer (≈ 45 pmol/min/mg) than in benign prostatic hyperplasia (≈ 2 pmol/min/mg). The protocol employed for preparing and measuring the NAALADase enzyme activity of the prostate specimens were the same as described above for FIG. 1.

FIG. 3 is a bar graph showing that NAALADase enzyme activity (picomoles/minute/milligram) in benign prostatic hyperplasia (≈ 2 pmol/min/mg) is significantly less than in normal prostate tissue (≈ 5 pmol/min/mg). The protocol employed for preparing and measuring the NAALADase enzyme activity of the prostate specimens were the same as described above for FIG. 1.

FIG. 4 is a bar graph showing that the ratio of membrane versus cytosolic NAALADase enzyme activity is especially significantly greater in prostate cancer (ratio ≈ 5.9) than in benign prostatic hyperplasia (ratio ≈ 2.0) or normal prostate tissue (ratio ≈ 2.3). The protocol employed for preparing and measuring the NAALADase enzyme activity of the prostate specimens were the same as described above for FIG. 1.

EXAMPLES

The following examples are illustrative of the present invention and are not intended to be limitations thereon. Unless otherwise indicated, all percentages are based upon 100% by weight of the final composition.

EXAMPLE 1

Assaying NAALADase Activity in Prostate Tissue of Prostate Cancer Patients

Prostates are removed from men undergoing radical prostatectomies as treatment for prostate cancer. After evaluation by a pathologist, the prostates were separated histologically into normal, BPH and tumor sections. The frozen tissue samples were resuspended in 10X volume of ice cold bakers water and minced by polytron. Following sonication, the tissue preparation was centrifuged at 50,000Xg at 4°C for 20 min. The supernatant (cytosolic fraction) was removed, divided into 1 ml aliquots and frozen at -80°C. The pellet was then resuspended in half the original volume of 50mM Tris-HCl buffer. This membrane fraction was again minced by polytron, sonicated and divided into 1 ml aliquots and frozen at -80°C. The NAALADase assay was performed as described by Slusher et al. (J. Biol. Chemistry 265:21297-21301, 1990). Briefly, CoCl₂ and tris-HCl pH 7.4 was added to known volumes of tissue extract. Following the addition of N-

acetyl-aspartate-L-³H-glutamate (NAAG), the sample was incubated at 37°C for 15 min and then passed through an ion exchange column to separate aspartate from the labeled glutamate [flow through]. The samples are then counted on a Beckman LS 6000 beta scintillation counter. The assay is followed by a Biorad protein assay to determine specific activity for each sample.

10

EXAMPLE 2

Assaying NAALADase Activity in Prostate Tissue to
Identify the Absence of Neoplastic Disease

A patient submits a prostate biopsy sample for analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that normal prostate tissue results indicate a lack of neoplastic disease.

EXAMPLE 3

20

Assaying NAALADase Activity in Prostate Tissue to
Identify the Presence of Benign Prostatic
Hyperplasia

A patient submits a prostate biopsy sample for analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that benign prostatic hyperplasia tissue results indicate a lack of prostate cancer.

EXAMPLE 4

Assaying NAALADase Activity in Prostate Tissue to
Differentiate Between the Presence of Prostate
Cancer, Benign Prostatic Hyperplasia, and Normal
5 Prostate

A patient submits a prostate biopsy sample for analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that prostate cancer tissue results
10 indicate a lack of benign prostatic hyperplasia. A patient whose prostate biopsy indicates the occurrence of prostate cancer and not benign prostatic hyperplasia would likely undergo aggressive treatment regimens including
15 prostatectomy, radiation therapy, and chemotherapy.

EXAMPLE 5

Assaying NAALADase Activity in Ejaculate to Identify
the Absence of Neoplastic Disease

20 A patient submits an ejaculate sample for analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that normal prostate results indicate a lack of neoplastic disease.

25

EXAMPLE 6

Assaying NAALADase Activity in Ejaculate to Identify
the Presence of Benign Prostatic Hyperplasia

-25-

A patient submits an ejaculate sample for analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that benign prostatic hyperplasia results indicate a lack of prostate cancer.

EXAMPLE 7

Assaying NAALADase Activity in Ejaculate to Differentiate Between the Presence of Prostate Cancer, Benign Prostatic Hyperplasia, and Normal Prostate

A patient submits an ejaculate sample for analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that prostate cancer results indicate a lack of benign prostatic hyperplasia. A patient whose ejaculate indicates the occurrence of prostate cancer and not benign prostatic hyperplasia would likely undergo aggressive treatment regimens including prostatectomy, radiation therapy, and chemotherapy.

EXAMPLE 8

Assaying NAALADase Activity in Ejaculate to Differentiate Between the Presence of Hormone-Responsive Prostate Cancer and Hormone-Refractory Prostate Cancer

A patient submits an ejaculate sample for

analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that prostate cancer results could be further differentiated between hormone-responsive prostate cancer and hormone-refractory prostate cancer.

EXAMPLE 9

Assaying NAALADase Activity in Ejaculate to Differentiate Between the Presence of Metastatic Prostate Cancer and Non-Metastatic Prostate Cancer

A patient submits an ejaculate sample for analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that prostate cancer results could be further differentiated between metastatic prostate cancer and non-metastatic prostate cancer.

EXAMPLE 10

Assaying NAALADase Activity in Ejaculate from a Patient Who Has Undergone Treatment for Prostate Cancer to Detect the Recurrence of Cancer

A patient undergoing treatment for prostate cancer, or who has previously undergone treatment for prostate cancer, submits an ejaculate sample for analysis. The sample is assayed according to the method described on pages 16-17. It would be expected that a prostate cancer result would

indicate the recurrence of prostate cancer.

EXAMPLE 11

Assaying NAALADase Activity in Urine to Identify the
5 Absence of Neoplastic Disease

A patient submits a urine sample for analysis.
The sample is assayed according to the method
described on pages 16-17. It would be expected that
normal prostate results indicate a lack of
10 neoplastic disease.

EXAMPLE 12

Assaying NAALADase Activity in Prostate Tissue to
 Identify the Presence of Benign Prostatic
15 Hyperplasia

A patient submits a urine sample for analysis.
The sample is assayed according to the method
described on pages 16-17. It would be expected that
benign prostatic hyperplasia results indicate a lack
20 of prostate cancer.

EXAMPLE 13

Assaying NAALADase Activity in Urine to
 Differentiate Between the Presence of Prostate
25 Cancer, Benign Prostatic Hyperplasia, and Normal
 Prostate

A patient submits a urine sample for analysis.
The sample is assayed according to the method

-28-

described on pages 16-17. It would be expected that prostate cancer results indicate a lack of benign prostatic hyperplasia. A patient whose urine NAALADase enzyme activity indicates the occurrence
5 of prostate cancer and not benign prostatic hyperplasia would likely undergo aggressive treatment regimens including prostatectomy, radiation therapy, and chemotherapy.

10

EXAMPLE 14

Assaying NAALADase Activity in Prostate Tissue Using
the Diagnostic Kit Disclosed by the Present
Invention to Identify the Absence of Neoplastic
Disease

15

A patient submits a prostate biopsy sample for analysis. The sample is assayed using the diagnostic kit employing the method described on pages 16-17. It would be expected that normal prostate tissue results indicate a lack of
20 neoplastic disease.

EXAMPLE 15

Assaying NAALADase Activity in Prostate Tissue Using
the Diagnostic Kit Disclosed by the Present
25 Invention to Identify the Presence of Benign
Prostatic Hyperplasia

A patient submits a prostate biopsy sample for analysis. The sample is assayed using the

-29-

diagnostic kit employing the method described on pages 16-17. It would be expected that benign prostatic hyperplasia tissue results indicate a lack of prostate cancer.

5

EXAMPLE 16

Assaying NAALADase Activity in Prostate Tissue Using
the Diagnostic Kit Disclosed by the Present
Invention to Differentiate Between the Presence of
10 Prostate Cancer, Benign Prostatic Hyperplasia, and
Normal Prostate

A patient submits a prostate biopsy sample for analysis. The sample is assayed using the diagnostic kit employing the method described on
15 pages 16-17. It would be expected that prostate cancer tissue results indicate a lack of benign prostatic hyperplasia. A patient whose prostate biopsy indicates the occurrence of prostate cancer and not benign prostatic hyperplasia would likely
20 undergo aggressive treatment regimens including prostatectomy, radiation therapy, and chemotherapy.

EXAMPLE 17

Assaying NAALADase Activity in Ejaculate Using the
25 Diagnostic Kit Disclosed by the Present Invention to
Differentiate Between the Presence of Prostate
Cancer, Benign Prostatic Hyperplasia, and Normal
Prostate

A patient submits an ejaculate sample for analysis. The sample is assayed using the diagnostic kit employing the method described on pages 16-17. A patient with a normal prostate would be expected to have ejaculate with NAALADase enzyme value near 5 pmol/min/mg, while the presence of BPH would reveal a NAALADase enzyme value near 2 pmol/min/mg. It would be expected that prostate cancer would result in a NAALADase enzyme value near 45 pmol/min/mg. A patient whose ejaculate indicates the occurrence of prostate cancer and not benign prostatic hyperplasia would likely undergo aggressive treatment regimens including prostatectomy, radiation therapy, and chemotherapy.

15

EXAMPLE 18

Assaying NAALADase Activity in Urine Using the Diagnostic Kit Disclosed by the Present Invention to Differentiate Between the Presence of Prostate Cancer, Benign Prostatic Hyperplasia, and Normal Prostate

20

A patient submits a urine sample for analysis. The sample is assayed using the diagnostic kit employing the method described on pages 16-17. A patient with a normal prostate would be expected to have urine with NAALADase enzyme value near 5 pmol/min/mg, while the presence of BPH would reveal a NAALADase enzyme value near 2 pmol/min/mg. It

25

-31-

would be expected that prostate cancer would result in a NAAALADase enzyme value near 45 pmol/min/mg. A patient whose urine indicates the occurrence of prostate cancer and not benign prostatic hyperplasia would likely undergo aggressive treatment regimens including prostatectomy, radiation therapy, and chemotherapy.

The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modification are intended to be included within the scope of the following claims.

15

What is claimed:

1. A method for detecting or identifying benign prostatic hyperplasia (BPH) or prostate cancer, comprising: comparing NAALADase activity in
5 a sample of prostate tissue or bodily fluid to a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby differential NAALADase activity between the
10 NAALADase activity in the sample of prostate tissue or bodily fluid and the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies benign prostatic
15 hyperplasia (BPH) or prostate cancer.

2. The method of claim 1, wherein the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic
20 hyperplasia, or prostate cancer is a quantitative value of a detectable metabolite of NAALADase activity.

3. The method of claim 2, wherein the
25 detectable metabolite results from NAALADase activity on a substrate selected from the group consisting of N-Acetyl Aspartyl Glutamate (NAAG), folate polyglutamate, derivatives thereof, and

substrates labeled with a radioactive marker,
chemiluminescent marker, enzymatic marker,
chromogenic marker, or other detectable marker.

5 4. The method of claim 1, wherein the
reference which correlates to NAALADase activity in
normal prostate tissue, benign prostatic
hyperplasia, or prostate cancer is a series of
standards which indicate a quantitative value of a
10 detectable metabolite of NAALADase activity.

 5. The method of claim 4, wherein the series
of standards which indicate a quantitative value of
the detectable metabolite is a gradient from lowest
15 to highest NAALADase activity wherein benign
prostatic hyperplasia exhibits a lower quantitative
value of the detectable metabolite than normal
prostate tissue and wherein prostate cancer exhibits
a higher quantitative value of the detectable
20 metabolite than normal prostate tissue.

 6. The method of claim 1, wherein the bodily
fluid is selected from the group consisting of
seminal vesicle fluid, ejaculate, prostatic fluid,
25 blood, saliva, and urine.

 7. A method for detecting or identifying
benign prostatic hyperplasia (BPH) or prostate

cancer, comprising: assaying NAALADase activity in a sample of prostate tissue or bodily fluid; and comparing the NAALADase activity in the sample of prostate tissue or bodily fluid to a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby differential NAALADase activity between the NAALADase activity in the sample of prostate tissue or bodily fluid and the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies benign prostatic hyperplasia (BPH) or prostate cancer.

8. The method of claim 7, wherein the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer is a quantitative value of a detectable metabolite of NAALADase activity.

9. The method of claim 8, wherein the detectable metabolite results from NAALADase activity on a substrate selected from the group consisting of N-Acetyl Aspartyl Glutamate (NAAG), folate polyglutamate, derivatives thereof, and substrates labeled with a radioactive marker, chemiluminescent marker, enzymatic marker,

chromogenic marker, or other detectable marker.

10. The method of claim 7, wherein the
reference which correlates to NAALADase activity in
5 normal prostate tissue, benign prostatic
hyperplasia, or prostate cancer is a series of
standards which indicate a quantitative value of a
detectable metabolite of NAALADase activity.

10 11. The method of claim 10, wherein the series
of standards which indicate a quantitative value of
the detectable metabolite is a gradient from lowest
to highest NAALADase activity wherein benign
prostatic hyperplasia exhibits a lower quantitative
15 value of the detectable metabolite than normal
prostate tissue and wherein prostate cancer exhibits
a higher quantitative value of the detectable
metabolite than normal prostate tissue.

20 12. The method of claim 7, wherein the bodily
fluid is selected from the group consisting of
seminal vesicle fluid, ejaculate, prostatic fluid,
blood, saliva, and urine.

25 13. A method for detecting or identifying a
pathological condition of prostate tissue,
comprising: assaying a sample of prostate tissue or
a bodily fluid for NAALADase activity; and comparing

the NAALADase activity of the sample of prostate tissue or bodily fluid to known NAALADase activity for normal prostate, benign prostatic hyperplasia, or prostate cancer, whereby differential NAALADase activity between the sample of prostate tissue or bodily fluid and the normal prostate, benign prostatic hyperplasia, or prostate cancer detects or identifies the pathological condition of the prostate tissue.

10

14. The method of claim 13, wherein the pathological condition of the prostate is benign prostatic hyperplasia or prostate cancer.

15

15. The method of claim 13, wherein the known NAALADase activity is a quantitative value of a detectable metabolite of NAALADase activity.

20

16. The method of claim 15, wherein the detectable metabolite results from NAALADase activity on a substrate selected from the group consisting of N-Acetyl Aspartyl Glutamate (NAAG), folate polyglutamate, derivatives thereof, and substrates labeled with a radioactive marker, chemiluminescent marker, enzymatic marker, chromogenic marker, or other detectable marker.

25

17. The method of claim 13, wherein the known

-37-

NAALADase activity is a series of standards which indicate a quantitative value of a detectable metabolite of NAALADase activity.

- 5 18. The method of claim 17, wherein the series of standards which indicate a quantitative value of the detectable metabolite is a gradient from lowest to highest NAALADase activity wherein benign prostatic hyperplasia exhibits a lower quantitative value of the detectable metabolite than normal prostate tissue and wherein prostate cancer exhibits a higher quantitative value of the detectable metabolite than normal prostate tissue.
- 10
- 15 19. The method of claim 13, wherein the bodily fluid is selected from the group consisting of seminal vesicle fluid, ejaculate, prostatic fluid, blood, saliva, and urine.
- 20 20. A method for detecting or identifying benign prostatic hyperplasia or prostate cancer, comprising measuring or assaying NAALADase activity in a sample of prostate tissue or bodily fluid wherein the NAALADase activity on a detectable or
- 25 labeled substrate of NAALADase results in a quantity of detectable or labeled metabolite; and comparing the quantity of labeled metabolite from the sample of prostate tissue or bodily fluid to at least one

-38-

reference or control wherein the reference or control represents a quantity of labeled metabolite from prostate tissue or bodily fluid which is indicative of non-neoplastic conditions, and whereby differential activity between the detectable or labeled metabolite from the sample of prostate tissue or bodily fluid and the control or reference quantity of labeled metabolite from normal prostate tissue or bodily fluid detects or identifies benign prostatic hyperplasia or prostate cancer.

21. The method of claim 20, wherein the substrate is selected from the group consisting of N-Acetyl Aspartyl Glutamate (NAAG), folate polyglutamate, derivatives thereof, and substrates labeled with a radioactive marker, chemiluminescent marker, enzymatic marker, chromogenic marker, or other detectable marker.

22. The method of claim 20, wherein the reference or control is a series of standards which is a gradient from lowest to highest NAALADase activity wherein benign prostatic hyperplasia exhibits a lower quantitative value of the detectable metabolite than normal prostate tissue and wherein prostate cancer exhibits a higher quantitative value of the detectable metabolite than normal prostate tissue.

23. The method of claim 20, wherein the bodily fluid is selected from the group consisting of seminal vesicle fluid, ejaculate, prostatic fluid, blood, saliva, and urine.

5

24. A method for detecting or identifying differential NAALADase activity in a sample of prostate tissue or bodily fluid, comprising: comparing NAALADase activity in a sample of prostate
10 tissue or bodily fluid to a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby comparing NAALADase activity between the sample of prostate tissue or bodily fluid and
15 the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies differential NAALADase activity.

20

25. The method of claim 24, wherein the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer is a quantitative value of a detectable metabolite of NAALADase
25 activity.

26. The method of claim 25, wherein the detectable metabolite results from NAALADase

-40-

activity on a substrate selected from the group consisting of N-Acetyl Aspartyl Glutamate (NAAG), folate polyglutamate, derivatives thereof, and substrates labeled with a radioactive marker, chemiluminescent marker, enzymatic marker, chromogenic marker, or other detectable marker.

27. The method of claim 24, wherein the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer is a series of standards which indicate a quantitative value of a detectable metabolite of NAALADase activity.

28. The method of claim 27, wherein the series of standards which indicate a quantitative value of the detectable metabolite is a gradient from lowest to highest NAALADase activity wherein benign prostatic hyperplasia exhibits a lower quantitative value of the detectable metabolite than normal prostate tissue and wherein prostate cancer exhibits a higher quantitative value of the detectable metabolite than normal prostate tissue.

29. The method of claim 24, wherein the bodily fluid is selected from the group consisting of seminal vesicle fluid, ejaculate, prostatic fluid, blood, saliva, and urine.

30. A method for detecting or identifying differential NAALADase activity in both the membrane and cytosolic fractions of a sample of prostate tissue or bodily fluid, comprising: comparing the
5 ratio of membrane NAALADase activity to cytosolic NAALADase activity in a sample of prostate tissue or bodily fluid to a reference which correlates to the ratio of membrane NAALADase activity to cytosolic NAALADase activity in normal prostate tissue, benign
10 prostatic hyperplasia, or prostate cancer, whereby comparing NAALADase activity between the sample of prostate tissue or bodily fluid and the reference which correlates to the ratio of membrane NAALADase activity to cytosolic NAALADase activity in normal
15 prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies differential NAALADase activity.

31. The method of claim 30, wherein the
20 reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer is a quantitative value of a detectable metabolite of NAALADase activity.

25

32. The method of claim 31, wherein the detectable metabolite results from NAALADase activity on a substrate selected from the group

consisting of N-Acetyl Aspartyl Glutamate (NAAG),
folate polyglutamate, derivatives thereof, and
substrates labeled with a radioactive marker,
chemiluminescent marker, enzymatic marker,
5 chromogenic marker, or other detectable marker.

33. The method of claim 30, wherein the
reference which correlates to NAALADase activity in
normal prostate tissue, benign prostatic
10 hyperplasia, or prostate cancer is a series of
standards which indicate a quantitative value of a
detectable metabolite of NAALADase activity.

34. The method of claim 33, wherein the series
15 of standards which indicate a quantitative value of
the detectable metabolite is a gradient from lowest
to highest NAALADase activity wherein benign
prostatic hyperplasia exhibits a lower quantitative
value of the detectable metabolite than normal
20 prostate tissue and wherein prostate cancer exhibits
a higher quantitative value of the detectable
metabolite than normal prostate tissue.

35. The method of claim 30, wherein the bodily
25 fluid is selected from the group consisting of
seminal vesicle fluid, ejaculate, prostatic fluid,
blood, saliva, and urine.

36. A kit for detecting or identifying benign prostatic hyperplasia (BPH) or prostate cancer in a sample of prostate tissue or bodily fluid, comprising: a detectable NAALADase enzyme substrate
5 packaged in a container; and a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby differential NAALADase activity between NAALADase activity in the sample of prostate
10 tissue or bodily fluid and the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies benign prostatic hyperplasia (BPH) or prostate cancer.

15

37. The kit of claim 36, wherein the substrate is selected from the group consisting of N-Acetyl Aspartyl Glutamate (NAAG), folate polyglutamate, derivatives thereof, and substrates labeled with a
20 radioactive marker, chemiluminescent marker, enzymatic marker, chromogenic marker, or other detectable marker..

38. The kit of claim 36, wherein the reference
25 which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer is a series of standards showing a gradient from lowest to highest NAALADase activity

wherein benign prostatic hyperplasia exhibits a lower quantitative value of the detectable metabolite than normal prostate tissue and wherein prostate cancer exhibits a higher quantitative value of the detectable metabolite than normal prostate tissue.

39. The kit of claim 36, wherein the bodily fluid is selected from the group consisting of seminal vesicle fluid, ejaculate, prostatic fluid, blood, saliva, and urine.

40. A kit for detecting or identifying a pathological condition of a prostate in a sample of prostate tissue or bodily fluid, comprising: a detectable NAALADase enzyme substrate packaged in a container; and a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer, whereby differential NAALADase activity between NAALADase activity in the sample of prostate tissue or bodily fluid and the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia (BPH), or prostate cancer detects or identifies benign prostatic hyperplasia (BPH) or prostate cancer.

41. The kit of claim 40, wherein the substrate

is selected from the group consisting of N-Acetyl
Aspartyl Glutamate (NAAG), folate polyglutamate,
derivatives thereof, and substrates labeled with a
radioactive marker, chemiluminescent marker,
5 enzymatic marker, chromogenic marker, or other
detectable marker.

42. The kit of claim 40, wherein the reference
which correlates to NAALADase activity in normal
10 prostate tissue, benign prostatic hyperplasia, or
prostate cancer is a series of standards showing a
gradient from lowest to highest NAALADase activity
wherein benign prostatic hyperplasia exhibits a
lower quantitative value of the detectable
15 metabolite than normal prostate tissue and wherein
prostate cancer exhibits a higher quantitative value
of the detectable metabolite than normal prostate
tissue.

20 43. The kit of claim 40, wherein the bodily
fluid is selected from the group consisting of
seminal vesicle fluid, ejaculate, prostatic fluid,
blood, saliva, and urine.

25 44. A kit for detecting or identifying
differential NAALADase activity in a sample of
prostate tissue or bodily fluid, comprising: a
detectable NAALADase enzyme substrate packaged in a

container; and a reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer.

5 45. The kit of claim 44, wherein the substrate is selected from the group consisting of N-Acetyl Aspartyl Glutamate (NAAG), folate polyglutamate, derivatives thereof, and substrates labeled with a radioactive marker, chemiluminescent marker,
10 enzymatic marker, chromogenic marker, or other detectable marker.

 46. The kit of claim 44, wherein the reference which correlates to NAALADase activity in normal
15 prostate tissue, benign prostatic hyperplasia, or prostate cancer is a series of standards showing a gradient from lowest to highest NAALADase activity wherein benign prostatic hyperplasia exhibits a lower quantitative value of the detectable
20 metabolite than normal prostate tissue and wherein prostate cancer exhibits a higher quantitative value of the detectable metabolite than normal prostate tissue.

25 47. The method of claim 44, wherein the bodily fluid is selected from the group consisting of seminal vesicle fluid, ejaculate, prostatic fluid, blood, saliva, and urine.

48. A kit for detecting or identifying differential NAALADase activity in both the membrane and cytosolic fractions of a sample of prostate tissue or bodily fluid, comprising: a detectable NAALADase enzyme substrate packaged in a container; and a reference which correlates to a ratio of membrane NAALADase activity to cytosolic NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer.

49. The kit of claim 48, wherein the substrate is selected from the group consisting of N-Acetyl Aspartyl Glutamate (NAAG), folate polyglutamate, derivatives thereof, and substrates labeled with a radioactive marker, chemiluminescent marker, enzymatic marker, chromogenic marker, or other detectable marker.

50. The kit of claim 48, wherein the reference which correlates to NAALADase activity in normal prostate tissue, benign prostatic hyperplasia, or prostate cancer is a series of standards showing a gradient from lowest to highest NAALADase activity wherein benign prostatic hyperplasia exhibits a lower quantitative value of the detectable metabolite than normal prostate tissue and wherein prostate cancer exhibits a higher quantitative value of the detectable metabolite than normal prostate

tissue.

41-

51. The method of claim 48, wherein the bodily
fluid is selected from the group consisting of
5 seminal vesicle fluid, ejaculate, prostatic fluid,
blood, saliva, and urine.

NAALADase activity is significantly greater
in prostate cancer than in normal prostate




FIG. 1

NAALADase levels are significantly greater
in prostate cancer than in BPH





FIG. 2

FIG. 3



The ratio of NAAL/NAAL' activity is significantly greater in cancer than in normal prostate or BPH




FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/25571

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/574 G01N33/573 C12Q1/37

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	BIOLOGICAL ABSTRACTS, Philadelphia PA USA; abstract no. PREV199900052186, see title XP002100797 & C.W. TIFFANY ET AL.: "Characterization of NAALADase activity in the prostate." SOCIETY FOR NEUROSCIENCES ABSTRACTS, vol. 24, no. 1-2, 7 November 1998, page 582 Los Angeles CA USA --- -/--	1-51

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Δ" document member of the same patent family

Date of the actual completion of the international search

21 April 1999

Date of mailing of the international search report

06/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fac (+31-70) 340-3016

Authorized officer

Van Bohemen, C

INTERNATIONAL SEARCH REPORT

Int .tional Application No
PCT/US 98/25571

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CHEMICAL ABSTRACTS, vol. 124, no. 11, 11 March 1996 Columbus, Ohio, US; abstract no. 139522, XP002100798 see abstract & R.E. CARTER ET AL.: "Prostate-specific membrane antigen is a hydrolase with substrate and pharmacological characteristics of a neuropeptidase." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE USA, vol. 93, no. 2, 1996, pages 749-753, Rockville MD USA</p> <p>-----</p>	1-51